Andrew Chan

About

Professor Andrew Chan is Head of the Medical Division Neuro, Inselspital, University Hospital of Bern. After studying medicine and obtaining a doctorate at the University of Hamburg, Professor Chan completed his specialist training at the University of Würzburg and continued his professional development as Senior Physician at the Universities of Göttingen and Bochum.
Professor Chan has published widely in the field of MS, including papers on molecular markers of disease progression and risk of immunotherapy, treatment optimisation and patient monitoring. He has been the Principal Investigator for several clinical studies in MS. He has also been involved in the development of national treatment guidelines. Professor Chan serves as board member for several societies, as associate editor for the European journal of neurology and as reviewer for different journals and research organizations.

Employment

• University Hospital of Bern Chief Physician, Deputy Head of Department, Head of Medical Division Neuro
  2016 - Present
• University of Bochum, Neurologische Klinik, St. Josef-Hospital, Klinikum der Ruhr Universität Bochum Chief Attending Specialist (Leitender Oberarzt)
  2007 - 2016
• Georg-August-Universität Göttingen Universitätsmedizin Attending Specialist (Oberarzt)
  2004 - 2006
• Universitätsklinikum Würzburg Resident Physician (Assistenzarzt)
  1995 - 2004

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (261)

• Feasibility of Privacy-Preserving LiDAR-Based Continuous Gait and Activity Monitoring in Three People with Multiple Sclerosis: A Technical Proof-of-Concept Case Study
  Sensors 2026 DOI: 10.3390/s26144455
  +Save
• Sex-Specific Differences in Amino Acids and Neurotransmitters in Multiple Sclerosis Patients Compared to Non-Neuroinflammatory Controls: A Retrospective Case-Control Study
  Neurochemical Research 2026 DOI: 10.1007/s11064-026-04766-y
  +Save
• Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study
  Video Journal of Biomedicine 2025 DOI: 10.1080/vjbm-2025-0004
  +Save
• Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation
  Exploration of Neuroscience 2025 DOI: 10.37349/en.2025.1006106
  +Save
• We’re all in this together: a rejoinder to Masud Husain’s (rant) editorial
  Brain 2025 DOI: 10.1093/brain/awaf139
  +Save
• SARS-CoV-2 Vaccines and Multiple Sclerosis
  Neurology Neuroimmunology & Neuroinflammation 2025 DOI: 10.1212/NXI.0000000000200393
  +Save
• Objective Sleep–Wake Findings in Patients with Post-COVID-19 Syndrome, Fatigue and Excessive Daytime Sleepiness
  Clinical and Translational Neuroscience 2025 DOI: 10.3390/ctn9010015
  +Save
• Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort
  Bioengineering 2024 DOI: 10.3390/bioengineering11080858
  +Save
• Recommendations for the Treatment of Multiple Sclerosis in Family Planning, Pregnancy and Lactation in Switzerland: Immunotherapy
  Clinical and Translational Neuroscience 2024 DOI: 10.3390/ctn8030026
  +Save
• The Swiss Brain Health Plan 2023–2033
  Clinical and Translational Neuroscience 2023 DOI: 10.3390/ctn7040038
  +Save